Amarin Corp Plcuk (AMRN) Long-Term Investments (2020 - 2023)
Amarin Corp Plc\Uk (AMRN) posted quarterly Long-Term Investments of $100000.0 for Q2 2023, down 99.12% year-over-year from $11.4 million in Q2 2022, and down 81.62% quarter-over-quarter from $544000.0 in Q1 2023.
Amarin Corp Plcuk (AMRN) Long-Term Investments (2020 - 2023) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Long-Term Investments for 4 consecutive years, with $100000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Long-Term Investments fell 99.12% year-over-year to $100000.0; the TTM figure through Jun 2023 stood at $100000.0 (down 99.12% YoY), while the FY2022 annual figure was $1.3 million, down 96.36% from the prior year.
- Long-Term Investments slipped to $100000.0 in Q2 2023 per AMRN's latest filing, from $544000.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $81.5 million in Q1 2020 and bottomed at $100000.0 in Q2 2023.
- Historically, Long-Term Investments has averaged $29.0 million across 4 years, with a median of $25.4 million in 2021.
- Annual changes were most pronounced in 2022 — Long-Term Investments rose 11.24% — and 2023, when it slumped 99.12%.
- Amarin Corp Plc\Uk's Long-Term Investments stood at $62.5 million in 2020, then slumped by 43.98% to $35.0 million in 2021, then sank by 96.36% to $1.3 million in 2022, then sank by 92.16% to $100000.0 in 2023.
- Business Quant data shows AMRN's Long-Term Investments at $100000.0 in Q2 2023, $544000.0 in Q1 2023, and $1.3 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | 544,000.00 |
| Dec 31, 2022 | 1.28 Mn |
| Sep 30, 2022 | 2.30 Mn |
| Jun 30, 2022 | 11.40 Mn |
| Mar 31, 2022 | 26.70 Mn |
| Dec 31, 2021 | 35.00 Mn |
| Sep 30, 2021 | 38.80 Mn |
| Jun 30, 2021 | 14.20 Mn |
| Mar 31, 2021 | 24.00 Mn |
| Dec 31, 2020 | 62.47 Mn |
| Sep 30, 2020 | 46.10 Mn |
| Jun 30, 2020 | 61.04 Mn |
| Mar 31, 2020 | 81.52 Mn |